<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02894138</url>
  </required_header>
  <id_info>
    <org_study_id>OPTIMAL-01</org_study_id>
    <nct_id>NCT02894138</nct_id>
  </id_info>
  <brief_title>Optimal Coronary Flow After PCI for Myocardial Infarction - a Pilot Study</brief_title>
  <acronym>OPTIMAL</acronym>
  <official_title>Optimal Coronary Flow After PCI for Myocardial Infarction - a Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vastra Gotaland Region</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vastra Gotaland Region</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study the investigators test the hypothesis that alteplase given intra coronary after
      PCI reduce infarct size in patients with ST-elevation myocardial infarction(STEMI) and
      impaired microvascular function defined as a value of index of microvascular resistance (IMR)
      &gt;30.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After coronary stenting, index of microvascular resistance (IMR) will be measured invasively.
      Patients with IMR &gt;30 will be randomised to 20 mg alteplase or placebo (NaCl) administered in
      the culprit vessel through a microcatheter. Magnet resonance imaging (MRI) of the myocardium
      will be performed early (2-6 days) and late (3 months) to estimate the primary endpoint
      (infarct size).

      10 non-randomised patients, with IMR &lt;30, will undergo the same follow-up as the randomised
      patients.

      Clinical events for all randomised and non-randomised patients will be collected from Swedish
      national registries and by telephone at 3 and 12 months.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">September 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ratio of myocardial infarct size to area at risk assessed by MRI</measure>
    <time_frame>3 months</time_frame>
    <description>MRI performed early (day 2-6) to assess area at risk and late (3 months) to assess infarct size</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change of index of microvascular resistance and coronary flow reserve</measure>
    <time_frame>Immediately after drug administration during invasive index procedure</time_frame>
    <description>Difference in invasively measured IMR and CFR before and after drug administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Degree of microvascular obstruction assessed by MRI</measure>
    <time_frame>2-6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak level of Troponin T</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Level of NtProBNP</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non invasive CFR</measure>
    <time_frame>3 months</time_frame>
    <description>CFR measured with transthoracic echo doppler</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event (myocardial infarction, stroke, heart failure or death)</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event (myocardial infarction, stroke, heart failure or death)</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalisation for heart failure</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Re-hospitalisation for myocardial infarction</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiovascular death</measure>
    <time_frame>12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Bleeding according to BARC-criteria</measure>
    <time_frame>7 days</time_frame>
    <description>Bleeding events during or after index PCI during index hospitalisation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Myocardial hemorrhage at MRI</measure>
    <time_frame>2-6 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin</measure>
    <time_frame>12 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>ST-segment Elevation Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>Alteplase</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>40 patients: 4-5 minutes of infusion of 10 ml of alteplase 2mg/ml in culprit vessel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>40 patients: 4-5 minutes of infusion of 10 ml of NaCl in culprit vessel</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Observational</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>10 patients with IMR &lt;30 will undergo the same follow-up as the randomised patients</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>alteplase</intervention_name>
    <arm_group_label>Alteplase</arm_group_label>
    <other_name>Actilyse®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Criteria for randomization:

        1. IMR measured in culprit vessel &gt; 30

        Criteria for IMR measurement:

        Inclusion Criteria:

          1. Oral and signed informed consent

          2. Males and females 18 - 85 years of age

          3. Diagnosis of ST-elevation myocardial infarction (STEMI) including occlusion of culprit
             vessel on angiography

          4. Onset of continuous symptoms within 12 hours

          5. Have undergone PCI of culprit vessel

          6. Subjects are willing to comply with scheduled visits and tests and are able and
             willing to provide informed consent

        Exclusion Criteria:

          1. Previously known ejection fraction &lt;30%

          2. Previous PCI in the culprit vessel

          3. Chronic total occlusion in major vessel

          4. Any history of bleeding diathesis, known coagulopathy, or will refuse blood
             transfusions

          5. Recent history or known platelet count &lt;100.000 cells/mm3 or Hbg &lt; 10 g/dL

          6. Known reduced kidney function with estimated glomerular filtration rate (GFR) &lt;30
             ml/min/1.73m2.

          7. Previous hemorrhagic stroke

          8. Ongoing oral anticoagulation treatment

          9. Severe asthma requiring daily treatment

         10. Any mechanical complication (e.g. ventricular septal defect, papillary muscle rupture,
             cardiac tamponade)

         11. Atrioventricular block grade III

         12. Known inability to undergo MRI investigation

             Permanent pacemaker

               -  Pronounced claustrophobia

         13. Known intolerance to study drug

         14. Known intolerance to adenosine

         15. Pregnancy

         16. Participation in another investigational drug study

         17. Previous randomization in the OPTIMAL-PCI trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oskar Angerås, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Oskar Angerås, MD, PhD</last_name>
    <phone>+46703134091</phone>
    <email>oskar.angeras@vgregion.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Cardiology, Sahlgrenska University Hospital</name>
      <address>
        <city>Gothenburg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Oskar Angerås, MD, PhD</last_name>
      <phone>+46703134091</phone>
      <email>oskar.angeras@vgregion.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <reference>
    <citation>Fearon WF, Shah M, Ng M, Brinton T, Wilson A, Tremmel JA, Schnittger I, Lee DP, Vagelos RH, Fitzgerald PJ, Yock PG, Yeung AC. Predictive value of the index of microcirculatory resistance in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2008 Feb 5;51(5):560-5. doi: 10.1016/j.jacc.2007.08.062.</citation>
    <PMID>18237685</PMID>
  </reference>
  <reference>
    <citation>Lim HS, Yoon MH, Tahk SJ, Yang HM, Choi BJ, Choi SY, Sheen SS, Hwang GS, Kang SJ, Shin JH. Usefulness of the index of microcirculatory resistance for invasively assessing myocardial viability immediately after primary angioplasty for anterior myocardial infarction. Eur Heart J. 2009 Dec;30(23):2854-60. doi: 10.1093/eurheartj/ehp313. Epub 2009 Aug 14.</citation>
    <PMID>19684025</PMID>
  </reference>
  <reference>
    <citation>Fearon WF, Low AF, Yong AS, McGeoch R, Berry C, Shah MG, Ho MY, Kim HS, Loh JP, Oldroyd KG. Prognostic value of the Index of Microcirculatory Resistance measured after primary percutaneous coronary intervention. Circulation. 2013 Jun 18;127(24):2436-41. doi: 10.1161/CIRCULATIONAHA.112.000298. Epub 2013 May 16.</citation>
    <PMID>23681066</PMID>
  </reference>
  <reference>
    <citation>Boscarelli D, Vaquerizo B, Miranda-Guardiola F, Arzamendi D, Tizon H, Sierra G, Delgado G, Fantuzzi A, Estrada D, Garcia-Picart J, Cinca J, Serra A. Intracoronary thrombolysis in patients with ST-segment elevation myocardial infarction presenting with massive intraluminal thrombus and failed aspiration. Eur Heart J Acute Cardiovasc Care. 2014 Sep;3(3):229-36. doi: 10.1177/2048872614527008. Epub 2014 Mar 17.</citation>
    <PMID>24637066</PMID>
  </reference>
  <reference>
    <citation>Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J, Kaul S, Wiviott SD, Menon V, Nikolsky E, Serebruany V, Valgimigli M, Vranckx P, Taggart D, Sabik JF, Cutlip DE, Krucoff MW, Ohman EM, Steg PG, White H. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation. 2011 Jun 14;123(23):2736-47. doi: 10.1161/CIRCULATIONAHA.110.009449.</citation>
    <PMID>21670242</PMID>
  </reference>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 24, 2016</study_first_submitted>
  <study_first_submitted_qc>September 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2016</study_first_posted>
  <last_update_submitted>September 12, 2016</last_update_submitted>
  <last_update_submitted_qc>September 12, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 13, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infarction</mesh_term>
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>ST Elevation Myocardial Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tissue Plasminogen Activator</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

